ScholarIQanswers from OpenAlex
AVEO Oncology (United States)
InstitutionResearch output, impact & collaborations
AVEO Oncology (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about AVEO Oncology (United States)?
ScholarIQrecord summary
AVEO Oncology (United States) is a research organisation in Cambridge, US. OpenAlex records 1,134 works and 120,536 citations for it. 533 researchers list it as their most recent affiliation.
How many works does AVEO Oncology (United States) have?
ScholarIQindexed works
AVEO Oncology (United States) has 1,134 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does AVEO Oncology (United States) have?
ScholarIQcitation count
AVEO Oncology (United States) has 120,536 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at AVEO Oncology (United States)?
ScholarIQresearcher count
AVEO Oncology (United States) has 533 researchers in the ScholarIQ index.
What is the average h-index at AVEO Oncology (United States)?
ScholarIQavg h-index
AVEO Oncology (United States) has an average h-index of 48.8 in OpenAlex.
What is the ROR of AVEO Oncology (United States)?
ScholarIQror
The ROR for AVEO Oncology (United States) is on the source record.
What is the OpenAlex record for AVEO Oncology (United States)?
ScholarIQopenalex
The OpenAlex for AVEO Oncology (United States) is on the source record.
Who are the most-cited researchers behind AVEO Oncology (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on AVEO Oncology (United States)?
ScholarIQmost cited works
Food, nutrition, physical activity, and the prevention of cancer: a global perspective
Michael Marmot, Tola Atinmo, T. Byers, Jun Chen, T Hirohata, Alun C. Jackson, William H. James, L N Kolonel, Shiriki Kumanyika, Claus Leitzmann, J Mann, Hilary J. Powers, K. Rama Reddy, Elio Ríboli, JA Rivera, Arthur Schatzkin, Jacob C. Seidell, David E. G. Shuker, Ricardo Uauy, Walter C. Willett, Steven H. Zeisel
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, H. Léna, Jesus Corral Jaime, Jhanelle E Gray, John D. Powderly, C. Chouaïd, Paolo Bidoli, Paul Wheatley‐Price, Keunchil Park, Ross A. Soo, Yifan Huang, Catherine Wadsworth, Phillip A. Dennis, Naiyer A. Rizvi, Luis Paz-Ares Rodríguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang‐We Kim, Jamie E. Chaft, David Vicente Baz, Thierry Berghmans, Dong‐Wan Kim, Veerle Surmont, Martin Reck, Ji‐Youn Han, Esther Holgado Martin, Cristóbal Belda-Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, G. Robinet, Héctor Soto Parrà, Michael J. Thomas, Parneet Cheema, Nobuyuki Katakami, Wu‐Chou Su, Young‐Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Stanislaw Milella, Inmaculada Ramos García, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, E. Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Rémi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan M. Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoîne Italiano, Dariusz M. Kowalski, Fabrice Barlési, Yuh‐Min Chen, David R. Spigel, Busyamas Chewaskulyong, Ramón García Gómez, Rosa Álvarez, Chih-Hsin Yang, Te‐Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Kōichi Goto, Joaquim Bosch‐Barrera, Glen J. Weiss, Jean-Luc Canon, Christian W. Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope A. Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn A. Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius F. Waller, David Waterhouse, Bruno Coudert, Z. Mark
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
Jhanelle E. Gray, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Byoung Chul Cho, David Planchard, Luis Paz‐Ares, Corinne Faivre‐Finn, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu, Scott Antonia
How much of the research on AVEO Oncology (United States) is open access?
ScholarIQopen access share
100%OPEN ACCESS